Do analysts recommend GMAB or NNNN?

Genmab A/S presently has a consensus price target of $37.93, indicating a potential upside of 51.74%. Given Genmab A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Genmab A/S is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.75 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, GMAB or NNNN?

Genmab A/S has higher revenue and earnings than Anbio Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.90B 4.00 $963M $1.32 18.94 Anbio Biotechnology $8.65M 407.27 $6.40M N/A N/A

Does the media prefer GMAB or NNNN?

In the previous week, Genmab A/S had 2 more articles in the media than Anbio Biotechnology. MarketBeat recorded 3 mentions for Genmab A/S and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.11 beat Genmab A/S's score of 0.66 indicating that Anbio Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anbio Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ASND or NNNN?

Ascendis Pharma A/S currently has a consensus price target of $295.39, suggesting a potential upside of 39.33%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascendis Pharma A/S is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 3.00 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, ASND or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than Ascendis Pharma A/S. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $865.78M 15.27 -$258M $8.67 24.45 Anbio Biotechnology $8.65M 407.27 $6.40M N/A N/A

Is ASND or NNNN more profitable?

Ascendis Pharma A/S has a net margin of 57.87% compared to Anbio Biotechnology's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S 57.87% N/A -8.37% Anbio Biotechnology N/A N/A N/A

Does the media prefer ASND or NNNN?

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Anbio Biotechnology. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 1 mentions for Anbio Biotechnology. Ascendis Pharma A/S's average media sentiment score of 1.36 beat Anbio Biotechnology's score of 1.11 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anbio Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SMMT or NNNN?

Summit Therapeutics presently has a consensus price target of $26.05, indicating a potential upside of 75.92%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Summit Therapeutics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 3 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.39 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, SMMT or NNNN?

Anbio Biotechnology has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A Anbio Biotechnology $8.65M 407.27 $6.40M N/A N/A

Is SMMT or NNNN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -291.24% -243.07% Anbio Biotechnology N/A N/A N/A

Does the media favor SMMT or NNNN?

In the previous week, Summit Therapeutics had 13 more articles in the media than Anbio Biotechnology. MarketBeat recorded 14 mentions for Summit Therapeutics and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.11 beat Summit Therapeutics' score of 0.33 indicating that Anbio Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Anbio Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NNNN or BBIO?

BridgeBio Pharma has a consensus target price of $89.59, indicating a potential upside of 31.60%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 BridgeBio Pharma 1 Sell rating(s) 2 Hold rating(s) 23 Buy rating(s) 0 Strong Buy rating(s) 2.85

Which has stronger valuation and earnings, NNNN or BBIO?

Anbio Biotechnology has higher earnings, but lower revenue than BridgeBio Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 407.27 $6.40M N/A N/A BridgeBio Pharma $579.96M 22.99 -$724.93M -$3.74 N/A

Is NNNN or BBIO more profitable?

Anbio Biotechnology has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A BridgeBio Pharma -124.42% N/A -65.81%

Does the media refer more to NNNN or BBIO?

In the previous week, BridgeBio Pharma had 5 more articles in the media than Anbio Biotechnology. MarketBeat recorded 6 mentions for BridgeBio Pharma and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.11 beat BridgeBio Pharma's score of 0.92 indicating that Anbio Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anbio Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate AXSM or NNNN?

Axsome Therapeutics presently has a consensus price target of $251.26, suggesting a potential upside of 4.06%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 1 Sell rating(s) 1 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.90 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, AXSM or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than Axsome Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Axsome Therapeutics $708.24M 17.54 -$183.17M -$3.73 N/A Anbio Biotechnology $8.65M 407.27 $6.40M N/A N/A

Does the media prefer AXSM or NNNN?

In the previous week, Axsome Therapeutics had 14 more articles in the media than Anbio Biotechnology. MarketBeat recorded 15 mentions for Axsome Therapeutics and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.11 beat Axsome Therapeutics' score of 0.36 indicating that Anbio Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anbio Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Anbio Biotechnology (NNNN) Competitors

$24.47 -2.54 (-9.39%)

As of 01:55 PM Eastern

Compare

NNNN vs. GMAB, ASND, SMMT, BBIO, and AXSM

Should you buy Anbio Biotechnology stock or one of its competitors? MarketBeat compares Anbio Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anbio Biotechnology include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Anbio Biotechnology compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

In the previous week, Genmab A/S had 2 more articles in the media than Anbio Biotechnology. MarketBeat recorded 3 mentions for Genmab A/S and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.11 beat Genmab A/S's score of 0.66 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anbio Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 21.05% compared to Anbio Biotechnology's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Anbio Biotechnology	N/A	N/A	N/A

Genmab A/S has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.90B	4.00	$963M	$1.32	18.94
Anbio Biotechnology	$8.65M	407.27	$6.40M	N/A	N/A

Genmab A/S presently has a consensus price target of $37.93, indicating a potential upside of 51.74%. Given Genmab A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Genmab A/S is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Genmab A/S has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.38, suggesting that its share price is 338% more volatile than the broader market.

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Genmab A/S beats Anbio Biotechnology on 12 of the 15 factors compared between the two stocks.

How does Anbio Biotechnology compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Anbio Biotechnology has lower revenue, but higher earnings than Ascendis Pharma A/S.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$865.78M	15.27	-$258M	$8.67	24.45
Anbio Biotechnology	$8.65M	407.27	$6.40M	N/A	N/A

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Anbio Biotechnology. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 1 mentions for Anbio Biotechnology. Ascendis Pharma A/S's average media sentiment score of 1.36 beat Anbio Biotechnology's score of 1.11 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anbio Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Anbio Biotechnology's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Anbio Biotechnology	N/A	N/A	N/A

Ascendis Pharma A/S currently has a consensus price target of $295.39, suggesting a potential upside of 39.33%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascendis Pharma A/S is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ascendis Pharma A/S has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.38, meaning that its stock price is 338% more volatile than the broader market.

Summary

Ascendis Pharma A/S beats Anbio Biotechnology on 8 of the 12 factors compared between the two stocks.

How does Anbio Biotechnology compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Anbio Biotechnology's return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Anbio Biotechnology	N/A	N/A	N/A

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Anbio Biotechnology has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Anbio Biotechnology	$8.65M	407.27	$6.40M	N/A	N/A

Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.38, suggesting that its stock price is 338% more volatile than the broader market.

In the previous week, Summit Therapeutics had 13 more articles in the media than Anbio Biotechnology. MarketBeat recorded 14 mentions for Summit Therapeutics and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.11 beat Summit Therapeutics' score of 0.33 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Anbio Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics presently has a consensus price target of $26.05, indicating a potential upside of 75.92%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Summit Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Summit Therapeutics beats Anbio Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Anbio Biotechnology compare to BridgeBio Pharma?

Anbio Biotechnology (NASDAQ:NNNN) and BridgeBio Pharma (NASDAQ:BBIO) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

BridgeBio Pharma has a consensus target price of $89.59, indicating a potential upside of 31.60%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

Anbio Biotechnology has a beta of 4.38, indicating that its share price is 338% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 5 more articles in the media than Anbio Biotechnology. MarketBeat recorded 6 mentions for BridgeBio Pharma and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.11 beat BridgeBio Pharma's score of 0.92 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.8% of BridgeBio Pharma shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Anbio Biotechnology has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
BridgeBio Pharma	-124.42%	N/A	-65.81%

Anbio Biotechnology has higher earnings, but lower revenue than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	407.27	$6.40M	N/A	N/A
BridgeBio Pharma	$579.96M	22.99	-$724.93M	-$3.74	N/A

Summary

BridgeBio Pharma beats Anbio Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Anbio Biotechnology compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Axsome Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.38, meaning that its share price is 338% more volatile than the broader market.

In the previous week, Axsome Therapeutics had 14 more articles in the media than Anbio Biotechnology. MarketBeat recorded 15 mentions for Axsome Therapeutics and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.11 beat Axsome Therapeutics' score of 0.36 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anbio Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics presently has a consensus price target of $251.26, suggesting a potential upside of 4.06%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Anbio Biotechnology has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Anbio Biotechnology's return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Anbio Biotechnology	N/A	N/A	N/A

Anbio Biotechnology has lower revenue, but higher earnings than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$708.24M	17.54	-$183.17M	-$3.73	N/A
Anbio Biotechnology	$8.65M	407.27	$6.40M	N/A	N/A

Summary

Axsome Therapeutics beats Anbio Biotechnology on 8 of the 15 factors compared between the two stocks.

Get Anbio Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNNN vs. The Competition

Export

Metric	Anbio Biotechnology	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.52B	$961.15M	$4.26B	$12.12B
Dividend Yield	N/A	N/A	7.93%	5.32%
P/E Ratio	N/A	N/A	21.76	23.83
Price / Sales	407.27	234.74	214.33	89.02
Price / Cash	640.59	640.59	53.68	55.53
Price / Book	116.54	60.75	28.38	6.45
Net Income	$6.40M	-$18.48M	$109.80M	$337.00M
7 Day Performance	-28.88%	-7.12%	-2.77%	-2.47%
1 Month Performance	-16.18%	9.55%	1.76%	1.01%
1 Year Performance	N/A	-57.72%	13.60%	29.30%

Anbio Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNNN Anbio Biotechnology	0.4983 of 5 stars	$24.47 -9.4%	N/A	N/A	$3.52B	$8.65M	N/A	27	Positive News
GMAB Genmab A/S	4.0357 of 5 stars	$26.86 -0.1%	$37.93 +41.2%	+13.5%	$16.71B	$3.90B	20.30	3,029
ASND Ascendis Pharma A/S	4.6561 of 5 stars	$235.33 -1.8%	$295.39 +25.5%	+26.0%	$14.72B	$814.57M	27.22	1,189	Positive News Short Interest Decrease
SMMT Summit Therapeutics	3.2052 of 5 stars	$17.13 +0.8%	$26.05 +52.1%	-24.1%	$13.29B	N/A	N/A	110	News Coverage Insider Trade Gap Up
BBIO BridgeBio Pharma	3.3625 of 5 stars	$65.85 -2.8%	$88.90 +35.0%	+77.1%	$12.91B	$579.96M	N/A	400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NNNN) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anbio Biotechnology (NNNN) Competitors

NNNN vs. GMAB, ASND, SMMT, BBIO, and AXSM

How does Anbio Biotechnology compare to Genmab A/S?

Summary

How does Anbio Biotechnology compare to Ascendis Pharma A/S?

Summary

How does Anbio Biotechnology compare to Summit Therapeutics?

Summary

How does Anbio Biotechnology compare to BridgeBio Pharma?

Summary

How does Anbio Biotechnology compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anbio Biotechnology (NNNN) Competitors

NNNN vs. GMAB, ASND, SMMT, BBIO, and AXSM

How does Anbio Biotechnology compare to Genmab A/S?

Does the media prefer GMAB or NNNN?

Is GMAB or NNNN more profitable?

Which has preferable valuation and earnings, GMAB or NNNN?

Do analysts recommend GMAB or NNNN?

Which has more volatility and risk, GMAB or NNNN?

Do institutionals and insiders believe in GMAB or NNNN?

Summary

How does Anbio Biotechnology compare to Ascendis Pharma A/S?

Which has better valuation and earnings, ASND or NNNN?

Does the media prefer ASND or NNNN?

Is ASND or NNNN more profitable?

Do analysts recommend ASND or NNNN?

Which has more risk & volatility, ASND or NNNN?

Summary

How does Anbio Biotechnology compare to Summit Therapeutics?

Is SMMT or NNNN more profitable?

Do insiders & institutionals believe in SMMT or NNNN?

Which has higher valuation & earnings, SMMT or NNNN?

Which has more risk and volatility, SMMT or NNNN?

Does the media favor SMMT or NNNN?

Do analysts recommend SMMT or NNNN?

Summary

How does Anbio Biotechnology compare to BridgeBio Pharma?

Do analysts prefer NNNN or BBIO?

Which has more volatility and risk, NNNN or BBIO?

Does the media refer more to NNNN or BBIO?

Do insiders and institutionals have more ownership in NNNN or BBIO?

Is NNNN or BBIO more profitable?

Which has stronger valuation and earnings, NNNN or BBIO?

Summary

How does Anbio Biotechnology compare to Axsome Therapeutics?

Which has more risk and volatility, AXSM or NNNN?

Does the media prefer AXSM or NNNN?

Do analysts rate AXSM or NNNN?

Do institutionals & insiders have more ownership in AXSM or NNNN?

Is AXSM or NNNN more profitable?

Which has higher valuation and earnings, AXSM or NNNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools